The Scientific Business of Thomson Reuters Publishes Pharma Matters; Three Pharmaceutical Reports Analyzing Activity From April - June 2008



    Each Report uses Market Intelligence and Competitive Analysis from
Thomson Reuters to Highlight Developments on the International Pharmaceutical
Pipeline
    LONDON and PHILADELPHIA, Oct. 1 /PRNewswire/ -- Thomson Reuters, the
world's leading source of intelligent information for businesses and
professionals, has announced the availability of three Pharma Matters reports
covering the time period April - June 2008. The quarterly Pharma Matters
reports cover all aspects of the pharmaceutical pipeline, leveraging strategic
intelligence and competitive analysis from Thomson Pharma(R), Newport Horizon
Premium(TM) and the Thomson Messaging Mapping SystemSM.
    


    
    Movers and Shakers - This report covers the US generics industry using
data and analysis from Newport Horizon Premium, the critical product targeting
the global business development system. Analysis from the Q2 2008 report
includes:
    

    --  The wave of M&A activity which had already been noted in the previous
        quarter continued unabated. The headline action for the sector was
        undoubtedly Daiichi Sankyo's (Japan) proposed acquisition of Ranbaxy
        (India).
    --  During the second quarter of 2008, final approvals were issued on 142
        'A'-rated ANDAs, up from 134 the quarter before.
    --  Seven new products (three combination products and four single active
        ingredient products) were subjected to paragraph IV challenges for the
        first time in Q2 2008, in comparison to the challenges made to 11 new
        products in the first quarter of 2008.
    --  During the second quarter of 2008, the largest number of ANDA
approvals
        went to India-based companies. Seventeen different India-based
        corporations received a total of 52 final ANDA approvals.
    --  In the same time period, 26 US-based companies received a total of 45
        approvals, putting the US in second place for this quarter.
    --  Sun Pharmaceutical of India received 11 final ANDA approvals, the
        greatest number of any individual group in Q2 2008. A number of those
        ANDAs were related to the compound amitriptyline.


    
    To learn more about companies making their mark on the US generics
market, click on this link to read the full report: 
http://scientific.thomsonreuters.com/thomsonpharma/media/pdfs/tpqr/movers_shak
er s_apr-jun_08.pdf
    


    
    Who is Making the Biggest Splash? - A Thomson Reuters expert review of
the organizations that are helping to shape professional opinions on drugs and
therapies, using the unique insights of the Thomson Message Mapping System. In
this quarterly review of the scientific literature on drugs and therapies,
Thomson Reuters assesses the quantity and quality of the materials published
by pharmaceutical companies, research institutions and other non-commercial
bodies. The top five of the 15 listed organizations that have made the biggest
impact as the leading sources of information on medical research from April -
June 2008 are:
    


    1. Novartis
    2. AstraZeneca
    3. Pfizer
    4. Bristol-Myers Squibb
    5. Merck


    
    To see the complete list, as well as analysis and methodology, click to
read the full report:
http://scientific.thomsonreuters.com/thomsonpharma/media/pdfs/tpqr/making-a-sp
la sh-june2008.pdf
    


    
    The Ones to Watch - A Thomson Reuters quarterly review of the latest
phase changes in the pharmaceutical pipeline, this report is based on the
strategic data and analysis from Thomson Pharma, the world's leading
pharmaceutical competitive intelligence solution. In the report covering Q2
2008, the top five most promising drugs launched or receiving approval were:
    


    

    
    DRUG              DISEASE                         COMPANY
    Panflu(TM)        Avian Influenza                 Sinovac/China CDC
    Luvox CR(R)       Obsessive compulsive
                       disorder, social anxiety       Jazz
                       disorder                        Pharmaceuticals/Solvay
    

    
    Treximet(TM)      Migraine                        POZEN/GlaxoSmithKline
    Relistor(TM)      Constipation in patients        Wyeth/Progenics
                        undergoing opioid treatment
    Lexiscan(TM)      Myocardial perfusion            CV Therapeutics/Astellas
                       imaging


    
    More analysis, as well as information on drugs entering clinical Phases
I, II and III, are available in the full report:
http://scientific.thomsonreuters.com/thomsonpharma/media/pdfs/tpqr/totw_apr-ju
n_ 08.pdf
    


    
    To sign up for the Thomson Reuters Pharma Matters series of publications
visit: scientific.thomson.com/pharma/forms/matters/
    


    About Thomson Reuters
    
    Thomson Reuters is the world's leading source of intelligent information
for businesses and professionals.  We combine industry expertise with
innovative technology to deliver critical information to leading decision
makers in the financial, legal, tax and accounting, scientific, healthcare and
media markets, powered by the world's most trusted news organization. With
headquarters in New York and major operations in London and Eagan, Minnesota,
Thomson Reuters employs more than 50,000 people in 93 countries. For more
information, go to thomsonreuters.com.
    




    




For further information:

For further information: Eoin Bedford of Scientific, +44-207-433-4691,
eoin.bedford@thomsonreuters.com Web Site: http://www.thomsonreuters.com


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890